Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Fenfluramine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 97,339Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FINTEPLA (OLE) Study Results In Lennox-Gastaut Syndrome Published
    FINTEPLA (OLE) Study Results In Lennox-Gastaut Syndrome Published

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/final-analysis-of-open-label-extension-ole-study-of-fintepla-fenfluramine-in-lennox-gastaut-syndrome-published-in-epilepsy--behavior-302583331.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    UCB's Fintepla shows potential to treat a 3rd epilepsy disorder
    UCB's Fintepla shows potential to treat a 3rd epilepsy disorder

    28 Jun 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ucbs-fintepla-shows-potential-expand-3rd-epilepsy-indication

    FIERCE PHARMA
    28 Jun 2025
    Share Share
    UCB Reports Positive Ph3 GEMZ Results in CDKL5 Disorder
    UCB Reports Positive Ph3 GEMZ Results in CDKL5 Disorder

    27 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ucb-announces-positive-results-from-gemz-phase-3-study-of-fenfluramine-in-cdkl5-deficiency-disorder-302492480.html

    PR NEWSWIRE
    27 Jun 2025
    Share Share
    Epilepsia Publishes FINTEPLA Long-Term Safety Data In Dravet
    Epilepsia Publishes FINTEPLA Long-Term Safety Data In Dravet

    12 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epilepsia-publishes-final-analysis-of-open-label-extension-study-of-long-term-safety-and-effectiveness-of-fintepla-fenfluramine-in-children-and-adults-with-dravet-syndrome-302400217.html

    PR NEWSWIRE
    12 Mar 2025
    Share Share
    FINTEPLA® (Fenfluramine) Results On Managing Seizures Published In Epilepsia
    FINTEPLA® (Fenfluramine) Results On Managing Seizures Published In Epilepsia

    24 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fintepla-fenfluramine-results-examining-its-impact-in-managing-generalized-tonic-clonic-seizures-in-developmental-and-epileptic-encephalopathies-published-in-epilepsia-302179742.html

    PR NEWSWIRE
    24 Jun 2024
    Share Share
    UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project
    UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project

    20 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240617167454/en

    BUSINESSWIRE
    20 Jun 2024
    Share Share